Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501.

China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

Zura Bio has initiated the Phase II TibuSURE trial to assess tibulizumab, in treating systemic sclerosis (SSc) in adult patients.

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.

Precision has gained the approval of its CTA in Hong Kong to study PBGENE-HBV in the Phase I trial for curing chronic hepatitis B.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for obesity.

AI continued to be shown as an invaluable tool with the potential to accelerate clinical trials and improve patient care.

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

Despite hitting its primary endpoints, the Novo Nordisk REDEFINE 1 Phase III trial saw patients achieving a weight loss of 22.7% after 68 weeks on CariSema. Credit: Getty Images / Bloomberg Danish ...